Annual report pursuant to Section 13 and 15(d)

DEVELOPMENT AWARDS AND DEFERRED REVENUE (Details Narrative)

v3.22.0.1
DEVELOPMENT AWARDS AND DEFERRED REVENUE (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Jul. 31, 2020
Jan. 26, 2018
May 31, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Entity Listings [Line Items]              
Revenue       $ 881,705 $ 3,937,230    
Additional paid in capital, fair value of warrant issued         807,149    
CFF Warrant [Member]              
Entity Listings [Line Items]              
Warrant exercisable price per share       $ 13.20      
Cystic Fibrosis Program Related Investment Agreement [Member] | Phase 2b Clinical Trial [Member]              
Entity Listings [Line Items]              
Royalty payable     $ 2,700,000        
Payments for royalty     $ 27,000,000        
Proceeds from investments on achieving milestones       $ 25,000,000      
Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]              
Entity Listings [Line Items]              
Gain Contingency, Unrecorded Amount   $ 25,000,000          
Investment Agreement [Member] | 2018 CFF Award [Member]              
Entity Listings [Line Items]              
Revenue       $ 881,705 3,937,230    
Investment Agreement [Member] | CFF Warrant [Member]              
Entity Listings [Line Items]              
Warrant to purchase of common stock       1,000,000      
Warrants expiration term       Jan. 26, 2025      
Investment Agreement [Member] | CFF Warrant [Member] | Immediately Exercisable Warrants [Member]              
Entity Listings [Line Items]              
Warrant to purchase of common stock       500,000      
Investment Agreement [Member] | CFF Warrant [Member] | Warrants Exercisable On Completion Of Final Milestone [Member]              
Entity Listings [Line Items]              
Warrant to purchase of common stock       500,000      
Investment Agreements [Member]              
Entity Listings [Line Items]              
Revenue $ 25,000,000     $ 2,500,000 $ 5,000,000 $ 5,000,000 $ 12,500,000
Investment Agreements [Member] | Cystic Fibrosis Foundation Warrants [Member]              
Entity Listings [Line Items]              
Revenue       25,000,000      
Additional paid in capital, fair value of warrant issued       6,215,225      
Revenue to be recognized       $ 18,784,775      
Collaboration Agreement [Member] | Cystic Fibrosis Foundation [Member]              
Entity Listings [Line Items]              
Royalty payment percentage   10.00%